Suppr超能文献

新辅助放化疗后行根治性食管切除术治疗初治不可切除胸段食管癌患者的疗效

Treatment results of neoadjuvant chemoradiotherapy followed by radical esophagectomy in patients with initially inoperable thoracic esophageal cancer.

作者信息

Morimoto Hideyuki, Fujiwara Yushi, Lee Shigeru, Amano Kosuke, Hosono Masako, Miki Yukio, Osugi Harushi

机构信息

Department of Radiation Oncology, Graduate School of Medicine, Osaka City University, 1-4-3, Asahimachi, Abeno-ku, Osaka, 545-8585, Japan.

Department of Gastroenterological Surgery, Graduate School of Medicine, Osaka City University, Osaka, Japan.

出版信息

Jpn J Radiol. 2018 Jan;36(1):23-29. doi: 10.1007/s11604-017-0693-0. Epub 2017 Oct 28.

Abstract

PURPOSE

We evaluated the effectiveness of neoadjuvant chemoradiotherapy (CRT) followed by esophagectomy for cT4 esophageal cancer or lymph node metastases (LNM) invading adjacent structures.

MATERIALS AND METHODS

We retrospectively evaluated 42 consecutive patients with thoracic esophageal cancer who underwent CRT followed by esophagectomy between 2008 and 2013. All were initially considered to be unresectable because of cT4 (n = 32) disease or LN invasion (n = 10). Radiotherapy was administered at 41.4 Gy/23 fr with concurrent chemotherapy. At completion of CRT, restaging was performed using computed tomography (CT).

RESULTS

All cT4 tumors were downstaged, LNM invading to adjacent structures were considered to be released, and subtotal esophagectomy was performed. The median follow-up period was 42 months. The curative resection (R0) rate was 94% in cT4 group and 70% in LN invasion group. The 3-year overall survival (OS) and 3-year locoregional control (LRC) rates were 65-80% in the cT4 group and 50-67% in LN invasion group, respectively.

CONCLUSIONS

The cT4 group showed good rates of R0, OS, and LRC. Surgical resection should be an effective option when downstaging is achieved by CRT for patients with initially inoperable thoracic esophageal cancer.

摘要

目的

我们评估了新辅助放化疗(CRT)联合食管切除术治疗cT4期食管癌或侵犯相邻结构的淋巴结转移(LNM)的有效性。

材料与方法

我们回顾性评估了2008年至2013年间连续42例行CRT联合食管切除术的胸段食管癌患者。所有患者最初均因cT4期疾病(n = 32)或淋巴结侵犯(n = 10)而被认为无法切除。放疗剂量为41.4 Gy/23次分割,并同步化疗。CRT结束后,使用计算机断层扫描(CT)进行重新分期。

结果

所有cT4期肿瘤均降期,侵犯相邻结构的LNM被认为已解除,遂行次全食管切除术。中位随访期为42个月。cT4组的根治性切除(R0)率为94%,淋巴结侵犯组为70%。cT4组的3年总生存率(OS)和3年局部区域控制(LRC)率分别为65 - 80%和50 - 67%。

结论

cT4组在R0、OS和LRC方面显示出良好的比率。对于最初无法手术的胸段食管癌患者,当通过CRT实现降期时,手术切除应是一种有效的选择。

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验